Overview

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Status:
Completed

Trial end date:
2019-05-01

Target enrollment:

Participant gender:

Summary

Patients with locally advanced resectable adenocarcinoma of the stomach or the esophagogastreal junction without previous therapy will be treated with one of two chemotherapy combinations before and after surgery. One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others Epirubicin, Cisplatin and 5-FU (ECF). Main objective of the study is median overall survival.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Krankenhaus Nordwest

Treatments:

Cisplatin
Docetaxel
Epirubicin
Fluorouracil
Leucovorin
Oxaliplatin